Nektar Therapeutics Debt and Lease Obligation
Nektar Therapeutics (NKTR) had Debt and Lease Obligation of $253.00 million as of 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Balance Sheet › Liabilities › Debt
us-gaap:DebtAndCapitalLeaseObligations · last filed 2017-11-08
- 2017-09-30: Debt and Lease Obligation $253.00M.
- 2017-06-30: Debt and Lease Obligation $253.80M.
- 2017-03-31: Debt and Lease Obligation $254.50M.
- 2016-12-31: Debt and Lease Obligation $255.10M.
| Period end | Debt and Lease Obligation |
|---|---|
| 2017-09-30 | $253.00M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $253.80M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $254.50M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $255.10M 10-K · filed 2017-03-01 |
| 2016-09-30 | $254.50M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $256.40M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $258.10M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $255.80M 10-K · filed 2016-02-29 |
| 2015-09-30 | $132.20M 10-Q · filed 2015-11-06 |
| 2013-12-31 | $160.80M 10-K · filed 2014-02-27 |
| 2013-09-30 | $147.60M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $147.70M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $148.90M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $149.00M 10-K · filed 2013-03-01 |
| 2012-09-30 | $152.00M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $239.00M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $240.00M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $239.90M 10-K · filed 2012-02-29 |
| 2011-09-30 | $239.80M 10-Q · filed 2011-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |